Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 20.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,761 shares of the company’s stock after buying an additional 301 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Amphastar Pharmaceuticals were worth $85,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Silvercrest Asset Management Group LLC increased its position in shares of Amphastar Pharmaceuticals by 35.1% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock valued at $4,937,000 after purchasing an additional 29,182 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Amphastar Pharmaceuticals during the second quarter worth $426,000. International Assets Investment Management LLC acquired a new stake in Amphastar Pharmaceuticals in the third quarter valued at $11,070,000. Nordea Investment Management AB raised its stake in Amphastar Pharmaceuticals by 0.4% in the first quarter. Nordea Investment Management AB now owns 333,014 shares of the company’s stock valued at $14,802,000 after buying an additional 1,209 shares in the last quarter. Finally, Granite Investment Partners LLC lifted its holdings in Amphastar Pharmaceuticals by 12.7% during the 2nd quarter. Granite Investment Partners LLC now owns 397,514 shares of the company’s stock worth $15,901,000 after buying an additional 44,744 shares during the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Trading Down 0.3 %

AMPH opened at $50.59 on Tuesday. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The business’s 50 day moving average is $48.34 and its two-hundred day moving average is $43.97. The firm has a market cap of $2.46 billion, a price-to-earnings ratio of 16.16, a price-to-earnings-growth ratio of 0.96 and a beta of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.75 by $0.10. The firm had revenue of $182.39 million during the quarter, compared to the consensus estimate of $171.29 million. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. On average, research analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.7 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on AMPH shares. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Finally, Piper Sandler lowered their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $63.00.

Insider Activity

In related news, Director Richard K. Prins sold 17,101 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $43.07, for a total transaction of $736,540.07. Following the transaction, the director now owns 33,971 shares of the company’s stock, valued at $1,463,130.97. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, Director Richard K. Prins sold 17,101 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $43.07, for a total transaction of $736,540.07. Following the completion of the sale, the director now directly owns 33,971 shares of the company’s stock, valued at $1,463,130.97. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total transaction of $139,410.00. Following the completion of the transaction, the director now directly owns 75,409 shares in the company, valued at $3,504,256.23. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 24,101 shares of company stock valued at $1,069,350. Insiders own 27.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.